Codon optimized rpgrorf15 genes and uses thereof

a technology of rpgrorf15 and rpgrorf15, which is applied in the field of cohrpgrorf15 genes, can solve the problems of poor sequence stability of wild type sequences, and achieve the effect of robust increase of cohrpgrorf15

Active Publication Date: 2022-03-03
4D MOLECULAR THERAPEUTICS INC
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is altering the nucleic acid to improve its performance. This can include changing certain parts of the sequence or increasing the frequency of certain parts. These changes can make the nucleic acid more efficient in producing a specific protein.

Problems solved by technology

However, poor sequence stability of the wild type sequence poses challenges to maintaining sequence integrity during vector production and suboptimal expression level of the wild type sequence in human photoreceptors are challenges to gene therapy approaches to treat XLRP.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

imization of RPGRorf15 cDNA Sequence with Improved Stability

[0155]The human Retinitis Pigmentosa GTPase Regulator open reading frame 15 (hRPGRorf15) sequence contains a highly repetitive, purine-rich region that leads to sequence instability during transgene cassette cloning and plasmid amplification. The hRPGRorf15 cDNA sequence (NCBI Reference Sequence NM_001034853.1) was codon optimized to generate an RPGRorf15 cDNA sequence with increased expression in human cells and improved sequence stability

[0156]The codon optimized nucleotide sequence is set forth below:

(SEQ ID NO: 10)ATGAGAGAGCCTGAAGAGCTGATGCCTGATAGCGGAGCAGTGTTTACCTTTGGGAAGAGCAAGTTCGCAGAGAATAACCCTGGGAAATTCTGGTTTAAGAACGACGTGCCCGTGCACCTGAGCTGTGGCGATGAGCACTCCGCCGTGGTGACAGGCAACAATAAGCTGTACATGTTCGGCTCTAACAATTGGGGACAGCTGGGCCTGGGAAGCAAGTCCGCCATCAGCAAGCCAACCTGCGTGAAGGCCCTGAAGCCCGAGAAGGTGAAGCTGGCCGCCTGTGGCAGAAACCACACACTGGTGAGCACCGAGGGAGGAAACGTGTACGCAACAGGAGGCAACAATGAAGGCCAGCTGGGCCTGGGCGACACAGAGGAGAGGAATACCTTTCACGTGATCAGCTTCTTTACCTC...

example 2

n and Activity of Human RPGRorf15 Protein Expressed from Codon Optimized hRPGRorf15 of SEQ ID NO:1

[0164]Expression and activity of human RPGRorf15 protein expressed from pAAV-GRK-cohRPGRorf15-5V40 was assessed in transfected HEK293T cells.

[0165]Briefly, HEK293T cells were seeded in 12-well plates at 2.0×10{circumflex over ( )}5 cells / well in 1.0 ml DMEM / 10% FBS media. HEK293T cells were used due to their high transfectability and protein expression. The next day, 1.0 μg AAV plasmid DNA complexed with 3.0 μl FuGene6 (Cat. #E2691, Promega, Madison, Wis.) was added to the cells in duplicate wells. Two days after transfection, the cells were washed with PBS and lysed in 0.25 ml 1× Passive Lysis Buffer (Promega) containing 1× Halt Protease Inhibitor (ThermoFisher), rocking for 15 minutes at room temperature. Cell debris was pelleted by centrifugation in a microcentrifuge at 12,000 g for 10 minutes at 4° C. The supernatant was collected and stored at −20° C. No-plasmid and pAAV-PGK promot...

example 3

l Expression of hRPGRorf15 in an In Vitro Model of Human XLRP

[0169]A human in vitro model system was generated to evaluate correction of the X-linked Retinitis Pigmentosa (XLRP) disease phenotype with the codon optimized human RPGRorf15 nucleic acid having the nucleotide sequence of SEQ ID NO:1. To that end, an AAV vector was constructed comprising the nucleotide sequence of SEQ ID NO:1 driven by the human G-protein coupled receptor rhodopsin kinase 1 (hGRK) promoter (i.e. the AAV vector backbone described in Examples 1 and 2, having the sequence of SEQ ID NO:5) and a variant capsid protein having the amino acid sequence of SEQ ID NO:9. The hGRK promoter was chosen to limit expression of RPGRorf15 to photoreceptors.

[0170]Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood drawn from individuals with XLRP and reprogrammed into induced pluripotent stem cells (iPSCs) using the CytoTune iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific, Waltham, Mass.). Pl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure provides codon optimized RPGRorf15 sequences, vectors, and host cells comprising codon optimized RPGRorf15 sequences, and methods of treating retinal disorders such as XLRP comprising administering to the subject a codon optimized RPGRorf15 sequence.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Patent Application Ser. No. 63 / 073,843, filed Sep. 2, 2020, the full disclosure of which is incorporated herein by reference.SEQUENCE LISTING SUBMISSION VIA EFS-WEB[0002]A computer readable text file, entitled “090400-5012-US-Sequence-Listing” created on or about Aug. 30, 2021, with a file size of about 37 KB contains the sequence listing for this application and is hereby incorporated by reference in its entirety.BACKGROUND OF THE INVENTION[0003]X-linked retinitis pigmentosa (XLRP) is a relatively severe and genetically heterogenous inherited retinal degeneration. Approximately 70% of XLRP cases are caused by mutations in the Retinitis Pigmentosa GTPase Regulator (RPGR) gene. The RPGR gene encodes several distinct alternatively-spliced transcripts that are widely expressed. The function of the encoded protein is not well understood, but studies suggest that it plays an important rol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/86A61K48/00A61K9/00A61P27/02
CPCC12N15/86A61P27/02A61K9/0048A61K48/005C12N2800/22C12N2750/14143C12N2830/008A61K48/0058A61K48/0066C07K14/4702A61K48/0041C12N2750/14171
Inventor KIRN, DAVID H.KOTTERMAN, MELISSA A.SCHAFFER, DAVIDFRANCIS, PETER
Owner 4D MOLECULAR THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products